Lumos Diagnostics Holdings (ASX:LDX) said its revenue for the six months ended Dec. 31, 2025, came in at AU$6.1 million, compared with AU$6.3 million in the prior-year period, according to a Friday Australian bourse filing.

Under its development agreement with Hologic, the company is working on the development of Hologic's fFN diagnostic product for pre-term birth, including adapting the test for use on Lumos' proprietary reader platform. The scope of work was expanded on three occasions, increasing total potential milestone payments to between AU$6.5 million and AU$7 million. The estimated project completion timeline was extended to February 2027.

The reduction in services revenue of AU$1 million during the period was driven by less revenue recognized from the intellectual property agreement with Hologic.

Lumos Diagnostics Holdings' shares rose nearly 3% in recent trading on Friday.